ReviewImmunology letters2020
"Cytokine storm", not only in COVID-19 patients. Mini-review.
Review in Immunology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Vaping-associated illness: a reassessment.International journal of emergency medicine · 2024Article
- Review
- SNP (A > G - rs13057211) but not GT(n) polymorphism in HMOX-1 promotor gene is associated with COVID-19 mortality.BMC pulmonary medicine · 2023Article
- IKK2/NFkB signaling controls lung resident CD8Nature communications · 2023Article
- Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.The Lancet. Respiratory medicine · 2022Review
- Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Article
- Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.International journal of molecular sciences · 2022Article
- Fostering experimental and computational synergy to modulate hyperinflammation.Trends in immunology · 2022Article
- Influenza virus causes lung immunopathology through down-regulating PPARγ activity in macrophages.Frontiers in immunology · 2022Article
- The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic.Biomedicines · 2021Review
- Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.International journal of molecular sciences · 2021Review
- Sea Urchin Pigments: Echinochrome A and Its Potential Implication in the Cytokine Storm Syndrome.Marine drugs · 2021Review
- A Timely Call to Arms: COVID-19, the Circadian Clock, and Critical Care.Journal of biological rhythms · 2021Review
- A Validated Mathematical Model of the Cytokine Release Syndrome in Severe COVID-19.Frontiers in molecular biosciences · 2021Article
- Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient's death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.